Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) went up by 10.43% from its latest closing price compared to the recent 1-year high of $4.25. The company’s stock price has collected -4.95% of loss in the last five trading sessions. Press Release reported 18 hours ago that Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
Is It Worth Investing in Entasis Therapeutics Holdings Inc. (NASDAQ :ETTX) Right Now?
Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Entasis Therapeutics Holdings Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $6.80. ETTX currently public float of 13.35M and currently shorts hold a 2.38% ratio of that float. Today, the average trading volume of ETTX was 265.21K shares.
ETTX’s Market Performance
ETTX stocks went down by -4.95% for the week, with a monthly drop of -2.31% and a quarterly performance of -33.02%, while its annual performance rate touched -22.71%. The volatility ratio for the week stands at 6.61% while the volatility levels for the past 30 days are set at 5.56% for Entasis Therapeutics Holdings Inc.. The simple moving average for the period of the last 20 days is 15.22% for ETTX stocks with a simple moving average of -5.65% for the last 200 days.
Analysts’ Opinion of ETTX
Many brokerage firms have already submitted their reports for ETTX stocks, with Cantor Fitzgerald repeating the rating for ETTX by listing it as a “Overweight.” The predicted price for ETTX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on September 09th of the previous year 2020.
ROTH Capital, on the other hand, stated in their research note that they expect to see ETTX reach a price target of $9. The rating they have provided for ETTX stocks is “Buy” according to the report published on July 13th, 2020.
ETTX Trading at -0.84% from the 50-Day Moving Average
After a stumble in the market that brought ETTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.18% of loss for the given period.
Volatility was left at 5.56%, however, over the last 30 days, the volatility rate increased by 6.61%, as shares surge +5.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.70% lower at present.
During the last 5 trading sessions, ETTX rose by +1.66%, which changed the moving average for the period of 200-days by -43.84% in comparison to the 20-day moving average, which settled at $2.03. In addition, Entasis Therapeutics Holdings Inc. saw -14.57% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ETTX starting from Innoviva, Inc., who purchase 4,672,897 shares at the price of $2.67 back on Sep 01. After this action, Innoviva, Inc. now owns 18,672,897 shares of Entasis Therapeutics Holdings Inc., valued at $12,499,999 using the latest closing price.
Innoviva, Inc., the 10% Owner of Entasis Therapeutics Holdings Inc., purchase 12,677,490 shares at $2.50 during a trade that took place back on Jun 11, which means that Innoviva, Inc. is holding 14,000,000 shares at $31,693,725 based on the most recent closing price.
Stock Fundamentals for ETTX
The total capital return value is set at -111.14, while invested capital returns managed to touch -104.69. Equity return is now at value -105.50, with -90.70 for asset returns.
Based on Entasis Therapeutics Holdings Inc. (ETTX), the company’s capital structure generated 2.53 points at debt to equity in total, while total debt to capital is 2.46. Total debt to assets is 2.15, with long-term debt to equity ratio resting at 1.35. Finally, the long-term debt to capital ratio is 1.31.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.02.